Darunavir/Ritonavir (Prezista) — Competitive Intelligence Brief

Darunavir/Ritonavir (Prezista) (Darunavir/Ritonavir (Prezista)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Darunavir/Ritonavir (Prezista) (Darunavir/Ritonavir (Prezista)) — Kowa Research Institute, Inc.. Darunavir is an HIV protease inhibitor that blocks the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Darunavir/Ritonavir (Prezista) TARGET	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
ATV/r	ATV/r	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	HIV protease inhibitor (boosted)	HIV protease
Atazanavir ritonavir	Atazanavir ritonavir	Göteborg University	marketed	HIV protease inhibitor	HIV protease
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Darunavir (DRV/r)	Darunavir (DRV/r)	Community Research Initiative of New England	marketed	HIV protease inhibitor	HIV protease
Lopinavir / Ritonavir	Lopinavir / Ritonavir	Baqiyatallah Medical Sciences University	marketed	HIV protease inhibitor	HIV protease
Darunavir/r	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class